Cross-Country Age Disparities in COVID-19 Cases with Hospitalization, ICU
Usage, and Morbidity
Enes Eryarsoy a and Dursun Delen b,#
c

Department of Management Information Systems, Sehir University,
Istanbul, Turkey. [eneseryarsoy@sehir.edu.tr]
a

Department of Management Science, Oklahoma State University,
Stillwater, OK, USA. [dursun.delen@okstate.edu]

Abstract
In this paper, we examine cross-country differences, in terms of the age distribution
of symptomatic cases, hospitalizations, intensive care unit (ICU) cases, and
fatalities due to the novel COVID-19. By calculating conditional probabilities, we
bridge country-level incidence data gathered from different countries and attribute
the variability in data to country demographics. We then provide case,
hospitalization, ICU, and fatality estimates for a comprehensive list of countries
using the existing data from a variety of countries.

1. Introduction and Background
The first COVID-19 outbreak took place in the city of Wuhan in the Hubei province of China.
Despite strict and robust prevention measures taken in the city, the virus has spread the rest of
the world in a matter of a few weeks. Within three months, the World Health Organization
(WHO) declared the outbreak a pandemic. While some more significantly than others, the virus
has taken its toll on all countries with no exception. The global impact of COVID-19 has been
very profound and probably unprecedented since the Spanish flu (H1N1 influenza circa 1918).
Due to the novelty of the virus, and the nonexistence of vaccination, health professionals have
been trying to cope with the pandemic using symptomatic treatment regimes. The rapid spread of
the virus has caused a record influx of patients at hospitals, pushing the primary care health
systems to the brink of total collapse. In order to ease the excessive burden on their healthcare
systems, the governments are seeking out ways to suppress the transmission of the virus.
1

The rapid spread of the virus has even made the calculation of the rate of spread difficult.
One frequently used way of measuring the spread is by computing the average number of
secondary cases, or infections, that each case generates. This is known as the R-naught (ğ‘…ğ‘…0 ) of
the virus. The ğ‘…ğ‘…0 â€™s time and place dependent nature (typically smaller in the South Asian

countries, depending on measures such as social distancing, isolation, partial or complete

lockdowns, quarantines by the local authorities) is making modeling the spread of the virus a
moving target (De Brouwer et al., 2020).
Even though the literature on COVID-19 is rapidly expanding, there is still a lack of
consensus among academics and other scientists on the dynamics of the spread. This can perhaps
be attributed to many reasons, such as the unpreparedness to a pandemic at this level, the lack of
unified reporting systems due to diversity of health systems across the world, and the novelty of
the pandemic itself. Many governments are seeking out forming different strategies that involve
mitigating the spread until a method of prevention or a well-defined, and a successful treatment
regime is found (Ferguson et al., 2020). The main focus of such mitigation effects is to alleviate
the burden on healthcare systems by spreading out the diffusion of cases over a more extended
period of time. While trying to achieve this, governments also face many uncertainties. One such
uncertainty involves the absence of proven methods to accurately estimate the potential demand
for healthcare services.
At the time of this paper's writing, several governments, such as Italy and Spain, already
had over 100% health services capacity utilization, while others were about to experience a
similar influx of critical patients. It is clear that governments are in need of better understanding
the dynamics of the spread for optimal or near-optimal resource allocation decisions.
Unfortunately, due to the emergency and the gravity of the pandemic and the lack of scantily
found hard evidence cause such decisions to be made through the seat-of-the-pants approaches.
Perhaps one of the reasons behind the lack of evidence is that there is no obvious way to
map reports and studies pertaining to one country into another. Many regional differences make
this mapping and transfer the learnings and knowledge over to another domain particularly
difficult. For the case of COVID-19, gender, and age of the patient populations seems to be
among the key drivers of such differences. Academics are acting swiftly to enrich the medical
literature by reporting their findings on the virus-related population characteristics, diffusion
patterns, treatment regimes, case dynamics, hospitalizations, ICU usages, and fatalities.
2

In this paper, we build on the studies and reports that involve age-based clinical fatality
risks (CFR), infection fatality risks (IFR), hospitalizations, ICU usages, and fatal outcomes.
Using the latest literature as well as expert opinions, we attempt to combine data from different
regions in order to estimate and highlight: (i) country-level differences, and (ii) healthcare
system demands for individual age groups. Specifically, using the data from six different
countries, we study the spread of the virus for different age groups.
While it is now known that the virus affects the elderly population more severely than the
youngers, studies often report inconsistent results. Several underlying reasons may explain these
inconsistencies. Perhaps one of the most plausible reason is the abundance of undocumented
cases. In their study, (Li et al., 2020b) highlight that one of the reasons for the rapid spread of the
virus is due to no documentation. They estimate that around 86% of all infections were
undocumented. Another study from South Korea suggests similar undocumented case
percentages at around 55-86% (Kim et al., 2020). News also suggests that even mortality cases
often go unreported. A recent article in The Economist (Fatal flaws, 2020) highlighted stark
differences between the number of expected death cases (including those attributed to COVID19) and the actual death cases. Their estimation, based on regionsâ€™ normal death rates, suggests
the actual death-toll of the novel COVID-19 being more than double of what is being reported in
different regions in Italy, Spain, and France. Perhaps this may be one of the reasons for
conflicting CFR and IFR figures reported in the literature. While some studies suggested an
estimated case fatality risk of as high as 7.2% (Onder et al., 2020) in Italy, other studies
suggested a CFR of 3.4% in China (Wilson et al., 2020), 2.3% using the age-adjusted Diamond
Princess cruise ship data (Russell et al., 2020). More recent works report somewhat lower case
fatality rates circa 1.4-1.5%% (Guan et al., 2020; Wu et al., 2020), both using data from Wuhan.
Similar variations also hold for IFR. Studies report IFRs such as 0.5% using the Diamond
Princess cruise ship data (Russell et al., 2020), 0.94%, and 0.657% using Wuhan data (Famulare,
2020) and (Verity et al., 2020), respectively. Even though these numbers significantly differ
from each other, there seems to be (i) convergence to a CFR of 1.5% over time, (ii) CFR/IFR
ratio appears to hover around 2-3, indicating as much as 40-70% asymptomatic cases of the
virus.
One of the apparent reasons behind the differences in reported CFRs is the different
demographics in different countries. As the virus affects the elderly more than the young, the
3

virus takes a different toll on each country, depending on its age demographics. There may be
several other reasons, including the fact that the age distribution of the infected population may
differ from the overall age distribution. Hence, ğ‘…ğ‘…0 may significantly differ across age groups. For

instance, a recent report indicated that the death-toll for under 60-year-old patients in Turkey is

as much as four times higher than that of the death-rates in other European countries. As Turkey
is one of the younger countries, this may be attributed to the demographical differences across
countries or even mobility differences across the same age groups in different countries.
In this study, we believe that we make two main contributions to the existing literature.
First, we investigate the role of age demographics on identified cases, hospitalization, ICU
usages, and fatalities across different countries. And then, by applying conditional probabilities
and the existing reports from different countries, we create a country independent conditional
probability for each group. Second, by coupling expert-formed scenarios for the US, with agestandardized rates estimated from different countries, we calculate the age breakdown of
symptomatic cases, hospitalizations, ICU usage, and fatalities.
In this study, we omit some critical analysis, such as taking into account gender
differences. In essence, the virus seems to affect males more than females, due to scarcity of
specific data, along with making some assumptions. For instance, we assume that deaths,

hospitalizations, and ICU usages are proxy measures for COVID-19 spread. We also assume that
similar spread patterns apply to each age group across countriesâ€”the virus is identical across all
countries. We also demonstrate some evidence for the acceptability of these assumptions. The
rest of this paper is organized as follows: in the next section, we describe our method and
elaborate on the data used. The final section is dedicated to the findings and related discussions.
2. Method and Dataset
Many of the existing studies focus on modeling the spread of the COVID-19 have been using a
few different models such as susceptible-infected-recovered (SIR) and its covariates (mainly
SEIR: susceptible-exposed-infected-recovered) (Fang et al., 2020; Liu et al., 2020; Peng et al.,
2020; Radulescu and Cavanagh, 2020), Sidarthe model (Giordano et al., 2020). These studies
often ignore age-dependent variations from one country to another, or are limited to one country,
or sometimes two (Ferguson et al., 2020).

4

In this study, instead of computing the spread of the virus, we look at the results of
different scenarios. We base our analyses on expert opinions and the existing data on specific
countries.
Expert opinions: Based on the characteristics of the COVID-19, Center for Disease
Control (CDC) estimated that 2.4 to 21 million Americans would require hospitalization, and a
death-toll of as much as 480,000 may be expected (Fink, 2020). According to the same
projection, the death toll could be any figure from 200,000 to as high as 1.7 million. Another
more recent estimate assuming full social distancing through May (as of April 8, 2020), the
White House estimated this figure to fall between 30,000 and 126,000 (Institute for Health
Metrics and Evaluation, 2020b).
While aggressive quarantines and enforcing/recommending social distancing can change
the outcome of the burden on healthcare systems, the primary health care capacities are the
bottleneck for almost all countries. The size of the susceptible population typically depends on
different ğ‘…ğ‘…0 values. By enforcing/recommending social distancing, governments attempt to

mitigate the situation and chance this figure (Figure 1).
100%
90%

R0=2.2, 84%

80%
70%
60%
50%

R0=1.3, 42.00%

40%
30%
20%
10%

Not infected

3

2.9

2.8

2.7

2.6

2.5

2.4

2.3

2.2

2

Susceptible (%)

2.1

1.9

1.8

1.7

1.6

1.5

1.4

1.3

1.2

1.1

1

0%
Seasonal Flu & Covid19

Figure 1. Different ğ‘…ğ‘…0 values and corresponding estimated percent of susceptible populations.

The novel coronavirus is often compared and contrasted against seasonal flu. Using CDC

numbers over the last two flu seasons (2017-2019), we estimate the following table for the
seasonal flu for comparison purposes.
5

Table 1. The seasonal flu numbers from CDC.
Seasonal Flu (based on CDC data)

US Cases

Susceptible population (R0=1.3)
Population with symptoms
Medical Visits
Hospitalization

134.4M
40M
15M
0.6M
40K

Fatality

CFR

As % of Susceptible
Population
100.00%
29.80%
11.10%
0.44%
0.03%

Per 1M
420,000
121K
45.5K
1,823
121

0.03%

We construct an analogous table to seasonal flu using expert opinions (Fink, 2020;
Institute for Health Metrics and Evaluation, 2020b). After carefully scanning the existing
literature, we built Table 2 outlining our analysis. We constructed different scenarios from more
severe (Scenario 1) to the least severe (Scenario 3) based on the estimates provided by the body
of experts. We construct this table for the United States. By making use of expert expectations
based on (Fink, 2020; Murray, 2020) we create a range of possible ğ‘…ğ‘…0 values to estimate the
percentage of susceptible population. Using the literature, we then estimate upper and lower
limits for symptomatic cases, reported cases (not all of the symptomatic cases are reported),

hospitalizations (as a percentage of reported cases), as well as ICU cases (in terms of cases), and
fatalities. One model (Murray, 2020) makes forecasts of the number of days will be needed,
while Spain data can be used to calculate this number directly (Ministerio de Sanidad, 2020).
After age-adjustments, we use data about hospitalizations as well as ICU usages from Spain.
Assuming 10-15 days of average stay (as suggested in the literature), the data are consistent with
those reported in (Murray, 2020).
Similarly, estimating fatalities also is difficult. Case fatality rates depend on a number of
factors, including:
(i)

The number of tests (and therefore the number of positive cases) conducted each
individual country. Many countriesâ€”excluding countries such as Iceland, where a
significant portion of the population was testedâ€”conduct selective testing. This
may involve a selection bias where only the people with severe enough symptoms
may be tested.

(ii)

The delay between the symptom onsets and the time of deaths.

(iii)

The varying levels of adequacy/inadequacy of the healthcare systems.
6

(iv)

The rates of smoking or the prevalence of chronical illnesses. We chose to use
CFR of 1.5% for the United States for our analysis.

Table 2. Different COVID-19 spread estimates for the United States (numbers are in millions)
COVID-19
1
Susceptible population (overall R0={2.2 , 1.8, 1.5 2}
The population with symptoms {.50 3, .35, .20 4}(C)
Reported cases (as the ratio of symptomatic
cases) {.11 5, .15, .20 6}
Hospitalizations (36% 78 of reported cases)(H)
ICU patients (% of Hospitalizationsâ€“7.4%

9,10

)(I)

Fatalities (D)

CFR {1.5 12,13}

Scenario 1
276.4
138

Scenario 2
240.2
84

Scenario 3
190.8
38

Expert
Opinion 1
160-210M
-

Expert
Opinion 2
-

27.6

13

4.2

-

-

10

4.5

1.5

2.4-21M

-

0.7
0.41

0.34
0.19

0.11
0.063

0.2-1.7M

~0.08 11
0.03-0.12

1.50%

1.50%

1.50%

In this study, we use country age distributions (using population pyramids) and data
involving different countries to create conditional probabilities. The severity of COVID-19 is
also gender-dependent. However, due to the unavailability of data, we did not take gender into
account.

(Li et al., 2020a): estimates ğ‘…ğ‘…0 value as 2.2 for Wuhan data.
(Shim et al., 2020) estimates ğ‘…ğ‘…0 value as 1.5 for South Korea where the virus is relatively better contained
3
(Wu et al., 2020) finds a 50% chance of developing symptoms using Wuhan data.
4
(Day, 2020) suggests that the ratio of asymptomatic cases could be as high as 80%.
5
(Lachmann et al., 2020) uses South Korean data and similar age corrections and estimate that only around 11% of
cases are reported in the US.
6
(Magal and Webb, 2020) uses an estimation interval of 40-60% in their analysis. However, we construct our
scenarios using similar to the US-based study.
7
(CDCMMWR, 2020a) CDC estimates also yield a similar number in the US. However, the data has no age
breakdown and includes some unknown cases.
8
The rate is estimated as 0.36 using conditional probabilities and age distributions based on Spanish Data
(Ministerio de Sanidad, 2020)
9
(Murray, 2020) estimates that around a fifth of hospitalization days will require ICU stays for the US. However,
they do not provide projections based on the number of hospitalization and ICU cases. Their numbers are in seem
consistent with Spanish data (Ministerio de Sanidad, 2020).
10
The crude rate is estimated as 7.4% of total hospitalizations using Spanish Data (Ministerio de Sanidad, 2020).
However, each case stays in ICU for an average of 15 days (European Society of Anaesthesiology, 2020). (0.074 x 15
= 1.11)
11
Assuming a 10-day average duration of stay.
12
(Guan et al., 0; Wu et al., 2020) indicated a CFR of 1.5%.
13
(Omer et al., 2020) indicates 0.7% CFR in Germany, such numbers usually come from countries where the spread
is better contained.
1
2

7

We report our findings using the mildest of the three scenarios. We use the following
notation:
E: Events, E = {C: Case, A: Age, H: Hospitalization, I: Intensive Unit Care, D: Death)
ğ‘ƒğ‘ƒ(ğ¶ğ¶): The probability of being infected with symptoms. Using the scenario-2 with

ğ‘…ğ‘…0 =1.8, we estimate the proportion of the susceptible population as 0.73, with a 35%
probability of developing symptoms: ğ‘ƒğ‘ƒ(ğ¶ğ¶) = 0.35 Ã— 0.73

ğ‘ƒğ‘ƒ(ğ‘…ğ‘…): The probability of being a reported case: ğ‘ƒğ‘ƒ(ğ‘…ğ‘…) = ğ‘ƒğ‘ƒ(ğ¶ğ¶) Ã— .15

ğ‘ƒğ‘ƒ(ğ»ğ»): The probability of hospitalization. This number depends on the percentage of

reported cases, as well as the size of the population with symptoms. Using 0.15 and 36%
of the rate of hospitalization we use (ğ‘ƒğ‘ƒ(ğ»ğ») = ğ‘ƒğ‘ƒ(ğ¶ğ¶) Ã— .11 Ã— .36)

ğ‘ƒğ‘ƒ(ğ¼ğ¼): The probability of needing ICU (ğ‘ƒğ‘ƒ(ğ¼ğ¼) = ğ‘ƒğ‘ƒ(ğ»ğ») Ã— 0.074)

ğ‘ƒğ‘ƒ(ğ·ğ·): The probability of death for the cases (CFR) (ğ‘ƒğ‘ƒ(ğ·ğ·) = ğ‘ƒğ‘ƒ(ğ‘…ğ‘…) Ã— .015)

ğ‘ƒğ‘ƒ(ğ´ğ´ğ‘–ğ‘– ): The probability of each age group i for a given country (using the country population
pyramid)

ğ‘ƒğ‘ƒ(ğ¶ğ¶|ğ´ğ´ğ‘–ğ‘– ): The probability of being infected with symptoms given age group i
ğ‘ƒğ‘ƒ(ğ´ğ´ğ‘–ğ‘– |ğ¶ğ¶): The probability of the age group i, given case.

We compute other conditional probabilities similarly for events {H, I, D}. We then use

the conditional probabilities to simulate the mild scenario breakdowns for the United States. By
using population pyramids and the US data, we replicate the same scenario for each individual
country and report the results (per 1 million residents).
ğ‘ƒğ‘ƒ(ğ¶ğ¶|ğ´ğ´) =

ğ‘ƒğ‘ƒ(ğ´ğ´|ğ¶ğ¶)
ğ‘ƒğ‘ƒ(ğ¶ğ¶)
ğ‘ƒğ‘ƒ(ğ´ğ´)

A sample table, including some of the probabilities using the reports by the Spanish
Ministry of Health, is given in Table 3. Using age-corrections via conditional probabilities also
shows that reported numbers are quite consistent across-countries (Table 4 and Figure 4).

8

Table 3. Probabilities and conditional probabilities for Spain
Age Group
0-9

P(A)

#Conf.
Cases

P(A|C)

#Hosp.

P(A|H)

#IUC
cases

P(A|I)

#Deaths

P(A|D)

9.3%

130

0.6%

35

0.45%

1

0%

0

0.0%

10-19

10.0%

226

1.1%

20

0.26%

1

0%

1

0.1%

20-29

10.0%

1,352

6.6%

200

2.6%

10

2%

4

0.5%

30-39

13.2%

2,386

11.7%

431

5.6%

18

3%

3

0.4%

40-49

17.0%

3,190

15.6%

778

10.1%

45

8%

9

1.1%

50-59

14.9%

3,433

16.8%

1,074

13.9%

106

18%

20

2.5%

60-69

11.1%

3,179

15.6%

1,432

18.6%

162

28%

63

7.8%

70-79

8.4%

3,304

16.1%

1,858

24.1%

192

34%

164

20.4%

80+

6.2%

3,271

16.0%

1,871

24.3%

38

7%

541

67.2%

Table 4. Computing age group probabilities for given cases in (i) Spain, (ii) in the US calculated using
Spain data 14 and (iii) reported by CDC 15. While the correlation between (i) and (iii) is .88, the correlation
between (i) and (ii) is as high as .97.
Age Group
0-9
10-19

ğ‘ƒğ‘ƒ(ğ´ğ´)ğ‘ˆğ‘ˆğ‘ˆğ‘ˆ

12.1%
12.9%

ğ‘ƒğ‘ƒ(ğ´ğ´)ğ‘†ğ‘†ğ‘†ğ‘†

9.3%

10.0%

ğ‘ƒğ‘ƒ(ğ´ğ´|ğ¶ğ¶ )ğ‘†ğ‘†ğ‘†ğ‘†

0.6%

ğ‘ƒğ‘ƒ(ğ´ğ´|ğ¶ğ¶ )ğ‘ˆğ‘ˆğ‘ˆğ‘ˆ from
Spain data
0.9%

ğ‘ƒğ‘ƒ(ğ´ğ´|ğ¶ğ¶ )ğ‘ˆğ‘ˆğ‘ˆğ‘ˆ
reported

2.5%

1.1%

1.6%

2.5%

20-29

14.0%

10.0%

6.6%

10.5%

11.5%

30-39

13.4%

13.2%

11.7%

13.3%

11.5%

40-49

12.2%

17.0%

15.6%

12.7%

14.5%

50-59

12.9%

14.9%

16.8%

16.4%

17.5%

60-69

11.5%

11.1%

15.5%

18.1%

17.1%

70-79

7.0%

8.4%

16.1%

15.1%

12.6%

80+

3.9%

6.2%

16.0%

11.4%

10.2%

We then use country demographics, CDC estimations for the US, and data sets available
(Table) to compute age-adjusted probabilities and number of cases for each of the events
(Susceptible, Case with symptoms, Hospitalization, IUC case, and Deaths) for countries with a

14
15

(Ministerio de Sanidad, 2020)
(CDCMMWR, 2020b)

9

population of more than 10 million people. We report all numbers per 1-million for ease of
comparison.
Table 5. Datasets used in this study
Country

South
Korea1

Spain2

US3

China4

Italy5

Number of cases

6,284

20,471

2,449

44,669

~34,000

Number of hospitalizations

-

7,699

-

-

-

Number of ICU cases

-

573

-

-

-

42

805

44

805

1,625

Number of fatalities
.(Shim et al., 2020)
2
.(Ministerio de Sanidad, 2020)
3
.(Shim et al., 2020)
4
.(Verity et al., 2020)
5
.(Onder et al., 2020)
1

Studies report different case- and death-related age-breakdowns for a variety of countries.
We observed that taking conditional probabilitiesâ€”based on population age distributions in
individual countriesâ€”into account, can help mitigate the variability in the reported results
(Figure 2).

Figure 2. Age breakdown patterns of cases with (left) and without (right) taking country population
pyramids (in terms of conditional probabilities) into account.

Figure 3 also highlights the age differences for different events. ICU beds and invasive
ventilators are in short supply, and some health systems prioritize younger patients over the older
ones in order to increase the chances of survival. While debated, the figure also demonstrates
such preferences.

10

Figure 3. Age pyramids for cases, hospitalization, ICU uses, and fatalities for Spain.

Unfortunately, the only source of data that explicitly provided the age breakdowns of
hospitalization and ICU cases (P(A|H), and P(A|I)) we could found was Spain (Ministerio de
Sanidad, 2020). After comparing the estimated P(H) and P(I)s from Spain data and the data from
the Institute for Health Metrics and Evaluation (2020), we concluded the numbers are consistent
and decided to use age breakdowns from the Spanish dataset.
Table 6. Conditional probabilities for hospitalization and ICU using Spain data.
Age Group
0-9

Hospitalized
35

P(A|H)
0.5%

ICU
1

P(A|I)
0.2%

10-19

20

0.3%

1

0.2%

20-29

200

2.6%

10

1.7%

30-39

431

5.6%

18

3.1%

40-49

778

10.1%

45

7.9%

50-59

1,074

13.9%

106

18.5%

60-69

1,432

18.6%

162

28.3%

70-79

1,858

24.1%

192

33.5%

80+

1,871

24.3%

38

6.6%
11

3. Results and Discussion
In this paper, we focus on age-dependent breakdowns of cases, hospitalizations, ICU usages, and
fatalities (events) using a range of scenarios. We construct these scenarios by using expert views
and existing reports in the literature and based on the US data. We then use conditional
probabilities to compute age-standardized breakdowns for the events for all individual countries.
Our results propose a few important implications. Firstly, the results highlight the effect
of demographical differences across countries on COVID-19 spread. They suggest that, provided
everything else remains the same, the death toll difference due to age demographics could be as
much as 20 times (Niger vs. Japan, Figure 4).
Secondly, our results have the potential to help decision-makers to accommodate agespecific aspects of the spread. Creating different age-based isolation strategies, depending on the
age-demographics of individual countries may be considered.
Also, our study attempts to combine several parameters calculated or taken from different
academic papers, reports, or data sources together in creating a range of scenarios. While this
approach provides a somewhat holistic view of the phenomenon, it also omits other country-level
differences such as social isolation policies, prevention strategies, the effectiveness of the
individual health-care systems. Our final table (Appendix-1) must be interpreted as a comparison
tool for different countriesâ€™ exposure to the virus.

Figure 4. Age-dependent event estimations for the US, the country with the youngest population in the
world (Niger), and with the oldest (Japan).
12

References
CDCMMWR (2020a). Preliminary Estimates of the Prevalence of Selected Underlying Health
Conditions Among Patients with Coronavirus Disease 2019 â€” United States, February
12â€“March 28, 2020. MMWR Morb. Mortal. Wkly. Rep. 69.
CDCMMWR (2020b). Severe Outcomes Among Patients with Coronavirus Disease 2019
(COVID-19) â€” United States, February 12â€“March 16, 2020. MMWR Morb. Mortal.
Wkly. Rep. 69.
Day, M. (2020). COVID-19: four-fifths of cases are asymptomatic, China figures indicate
(British Medical Journal Publishing Group).
De Brouwer, E., Raimondi, D., and Moreau, Y. (2020). Modeling the COVID-19 outbreaks and
the effectiveness of the containment measures adopted across countries. MedRxiv.
European Society of Anaesthesiology (2020). Analysis of COVID-19 data on numbers in
intensive care from Italy: European Society of Anaesthesiology (ESA).
Famulare, M. (2020). 2019-nCoV: Preliminary Estimates of the Confirmed-Case-Fatality-Ratio
and Infection-Fatality-Ratio, and Initial Pandemic Risk Assessment. v2. 0.
Fang, Y., Nie, Y., and Penny, M. (2020). Transmission dynamics of the COVID-19 outbreak and
effectiveness of government interventions: A data-driven analysis. J. Med. Virol.
Ferguson, N., Laydon, D., Nedjati Gilani, G., Imai, N., Ainslie, K., Baguelin, M., Bhatia, S.,
Boonyasiri, A., Cucunuba Perez, Z., Cuomo-Dannenburg, G., et al. (2020). Report 9:
Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and
healthcare demand.
Fink, S. (2020). Worst-Case Estimates for U.S. Coronavirus Deaths. N. Y. Times.
Giordano, G., Blanchini, F., Bruno, R., Colaneri, P., Di Filippo, A., Di Matteo, A., Colaneri, M.,
and others (2020). A SIDARTHE Model of COVID-19 Epidemic in Italy. ArXiv Prepr.
ArXiv200309861.
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D.S.C.
(2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.
0, null.
Institute for Health Metrics and Evaluation (2020). IHME | COVID-19 Projections.
Kim, D.-H., Choe, Y.J., and Jeong, J.-Y. (2020). Understanding and Interpretation of Case
Fatality Rate of Coronavirus Disease 2019. J Korean Med Sci 35.
Lachmann, A., Jagodnik, K.M., Giorgi, F.M., and Ray, F. (2020). Correcting under-reported
COVID-19 case numbers: estimating the true scale of the pandemic. MedRxiv.
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y.,
Wong, J.Y., et al. (2020a). Early Transmission Dynamics in Wuhan, China, of Novel
Coronavirusâ€“Infected Pneumonia. N. Engl. J. Med. 382, 1199â€“1207.
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., and Shaman, J. (2020b). Substantial
undocumented infection facilitates the rapid dissemination of novel coronavirus (SARSCoV2). Science.
13

Liu, Y., Gayle, A.A., Wilder-Smith, A., and RocklÃ¶v, J. (2020). The reproductive number of
COVID-19 is higher compared to SARS coronavirus. J. Travel Med.
magal, pierre, and Webb, G. (2020). Predicting the number of reported and unreported cases for
the COVID-19 epidemic in South Korea, Italy, France and Germany. MedRxiv.
Ministerio de Sanidad (2020). ActualizaciÃ³n no 54. Enfermedad por el coronavirus (COVID-19).
Murray, C.J. (2020). Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilatordays and deaths by US state in the next 4 months. MedRxiv.
Omer, S.B., Malani, P., and del Rio, C. (2020). The COVID-19 Pandemic in the US: A Clinical
Update. JAMA.
Onder, G., Rezza, G., and Brusaferro, S. (2020). Case-fatality rate and characteristics of patients
dying in relation to COVID-19 in Italy. JAMA.
Peng, L., Yang, W., Zhang, D., Zhuge, C., and Hong, L. (2020). Epidemic analysis of COVID19 in China by dynamical modeling. ArXiv Prepr. ArXiv200206563.
Radulescu, A., and Cavanagh, K. (2020). Management strategies in a SEIR model of COVID 19
community spread.
Russell, T.W., Hellewell, J., Jarvis, C.I., van-Zandvoort, K., Abbott, S., Ratnayake, R., Flasche,
S., Eggo, R.M., Kucharski, A.J., group, C. nCov working, et al. (2020). Estimating the
infection and case fatality ratio for COVID-19 using age-adjusted data from the outbreak
on the Diamond Princess cruise ship. MedRxiv.
Shim, E., Tariq, A., Choi, W., Lee, Y., and Chowell, G. (2020). Transmission potential and
severity of COVID-19 in South Korea. Int. J. Infect. Dis. 93, 339â€“344.
Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg,
G., Thompson, H., Walker, P.G., Fu, H., et al. (2020). Estimates of the severity of
coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis.
Wilson, N., Kvalsvig, A., Barnard, L.T., and Baker, M.G. (2020). Case-Fatality Risk Estimates
for COVID-19 Calculated by Using a Lag Time for Fatality. Emerg. Infect. Dis. 26.
Wu, J.T., Leung, K., Bushman, M., Kishore, N., Niehus, R., de Salazar, P.M., Cowling, B.J.,
Lipsitch, M., and Leung, G.M. (2020). Estimating clinical severity of COVID-19 from
the transmission dynamics in Wuhan, China. Nat. Med.
Fatal flaws (2020). COVID-19â€™s death toll appears higher than official figures suggest | Graphic
detail | The Economist.

14

Appendix 1
Table 7. Scenario-2 based event breakdowns for individual countries.
Population
(K)

Cases per
1M

Hosp. per
1M

ICU per
1M

Deaths
per 1M

Country

10,196

275,770

16,717

1,218

854

Portugal

83,783

275,671

16,521

1,194

852

Germany

60,461

275,463

16,903

1,223

902

Italy

10,423

273,517

16,472

1,173

879

Greece

8,655

272,148

15,554

1,130

720

Switzerland

6,949

271,055

16,053

1,216

706

Bulgaria

126,475

271,042

17,430

1,256

1,037

9,660

270,439

15,464

1,160

665

Hungary

5,542

270,389

16,135

1,195

784

Finland

17,136

269,922

15,626

1,169

705

Netherlands

46,733

269,495

15,673

1,117

772

Spain

51,270

269,133

14,500

1,102

556

Republic of Korea

19,236

268,786

15,330

1,133

677

Romania

37,847

267,820

15,109

1,113

656

Poland

11,589

267,496

15,314

1,104

736

Belgium

5,792

266,784

15,340

1,144

694

Denmark

10,708

265,466

15,251

1,153

642

Czechia

10,099

264,504

15,248

1,108

729

Sweden

67,886

264,035

14,909

1,078

694

United Kingdom

43,734

263,634

14,445

1,065

598

Ukraine

5,421

261,559

14,405

1,060

619

Norway

11,326

260,576

13,965

1,038

562

Cuba

9,449

256,685

13,641

1,004

548

Belarus

329,064

255,500

13,797

1,021

575

US

4,822

254,069

13,778

1,022

576

New Zealand

25,498

253,440

13,696

993

590

Australia

145,935

253,217

13,567

997

551

Russian Federation

3,474

244,333

12,945

912

586

Uruguay

4,938

242,002

12,670

941

493

Ireland

19,116

234,534

11,579

853

429

Chile

1,439,324

227,809

10,805

875

326

China

Japan

15

Population
(K)

Cases per
1M

Hosp. per
1M

ICU per
1M

Deaths
per 1M

45,197

213,004

10,468

759

400

Argentina

8,655

211,875

10,745

771

438

Israel

21,413

211,258

10,060

822

304

Sri Lanka

212,560

207,735

9,592

722

318

Brazil

50,883

198,163

9,060

679

301

Colombia

7,794,799

197,313

9,131

688

304

World

11,819

196,661

8,884

680

281

Tunisia

84,339

195,387

8,928

677

290

Turkey

32,972

191,468

8,717

649

290

Peru

97,338

190,509

8,391

608

284

Viet Nam

18,776

181,352

8,042

604

258

Kazakhstan

28,437

180,853

8,072

628

247

Venezuela (Bolivarian Republic of)

128,933

177,978

7,887

589

256

Mexico

10,847

174,998

7,815

574

263

Dominica

10,139

173,391

7,261

557

214

Azerbaijan

17,643

173,165

7,726

571

257

Ecuador

36,910

172,690

7,503

604

214

Morocco

32,365

168,392

7,211

575

205

Malaysia

11,674

163,184

7,436

533

267

Bolivia

83,993

161,603

6,787

541

189

Iran (Islamic Republic of)

43,852

159,997

6,934

521

217

Algeria

7,132

155,116

6,797

516

213

Paraguay

1,380,004

154,638

6,475

529

176

India

273,523

154,124

6,343

531

165

Indonesia

164,690

142,614

5,915

448

177

Bangladesh

109,581

136,985

5,625

457

152

Philippines

29,138

133,698

5,539

465

145

Nepal

59,308

132,704

5,360

455

135

South Africa

6,031

129,106

5,120

398

143

Turkmenistan

102,335

129,065

5,306

440

140

Egypt

33,470

128,528

5,038

401

135

Uzbekistan

17,500

125,473

5,083

400

141

Syrian Arab Republic

220,892

112,174

4,521

370

119

Pakistan

Country

16

Population
(K)

Cases per
1M

Hosp. per
1M

ICU per
1M

Deaths
per 1M

Country

10,205

108,890

4,301

345

114

Jordan

34,815

102,129

3,777

317

91

Saudi Arabia

43,849

93,224

3,681

308

93

Sudan

114,964

88,752

3,545

291

93

Ethiopia

40,223

88,523

3,410

280

87

Iraq

40,223

88,523

3,410

280

87

Iraq

11,195

85,682

3,366

285

84

South Sudan

5,101

85,658

3,307

278

82

State of Palestine

27,692

82,226

3,138

265

77

Madagascar

31,073

79,587

2,934

280

63

Ghana

16,745

77,735

2,989

261

71

Senegal

89,561

76,412

2,970

255

72

Democratic Republic of the Congo

29,825

74,766

2,840

250

67

Yemen

31,255

71,548

2,752

239

66

Mozambique

15,893

70,564

2,714

242

63

Somalia

26,378

68,960

2,558

243

55

CÃ´te d'Ivoire

26,545

68,088

2,540

232

57

Cameroon

59,734

66,731

2,484

229

55

United Republic of Tanzania

38,928

66,159

2,469

227

55

Afghanistan

53,771

66,064

2,407

219

53

Kenya

206,139

60,712

2,193

228

43

Nigeria

20,903

60,006

2,200

209

47

Burkina Faso

20,249

59,879

2,230

207

49

Mali

24,207

59,262

2,215

215

47

Niger

17

